REGENXBIO reported strong Q2 2026 results, highlighted by the Phase III AFFINITY DUCHENNE trial meeting its primary endpoint and dosing the first patient in the NAAVIGATE diabetic retinopathy study. The company secured over $200 million in new capital in July, extending its cash runway into Q4 2027. Key upcoming milestones include initiating the RGX-202 BLA submission in Q3 2026 with potential accelerated approval in 2H 2027, and pivotal data for wet AMD expected in Q4 2026. These advances position REGENXBIO to deliver transformative gene therapies for rare neuromuscular and retinal diseases.
Among four Dividend Aristocrats highlighted a year ago, AbbVie and Becton Dickinson outperformed the market with strong dividend growth and solid financials, while Procter & Gamble and Brown-Forman lagged in price but maintained reliable dividend pay...
The healthcare sector has led all S&P 500 sectors with a 13.10% gain over the past three months, despite lagging year-to-date. Major pharmaceutical companies Eli Lilly, Johnson & Johnson, and AbbVie offer a mix of growth and income, with strong recen...
Nxera Pharma announced a net profit of JPY 1,591 million (US$10.1 million) for Q2 2026, reversing a prior loss due to multiple milestone payments from partners like Neurocrine, AbbVie, and Lilly. The company progressed regulatory approvals and commer...
